484 articles in this topic
Leukemic stem cells produce their own ketone bodies to block ferroptosis, revealing a metabolic weak point that could be targeted therapeutically.
Researchers mapped distinct cell populations in human pancreatic ducts, finding two subtypes that drive aggressive, lower-survival pancreatic cancer.
A phase 1 trial finds intraventricular nivolumab is safe for leptomeningeal metastases, with median survival of 6.6 months.
A large genomic study finds mesenchymal glioblastoma responds better to immune checkpoint blockade, opening a path to smarter patient selection.
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
Inhibiting the mitophagy kinase PINK1 amplifies mitochondrial ROS, activating a BAX-caspase-GSDME cascade that destroys neuroblastoma cells via pyroptosis.
END-seq reveals ALT-positive cancer telomeres share canonical 5′ ATC termini with normal cells, but harbor uniquely abundant single-stranded DNA regions.
A landmark WGS study of 1,804 myeloid neoplasia patients uncovers how telomere length varies by mutation type and cancer subtype.
Intratumoral senescent cells shielded by PD-L2 may explain why chemotherapy often falls short — and point to a new combination strategy.
New review reveals how cancer biology has fundamentally transformed our understanding of mitochondrial plasticity and its implications beyond oncology.
A phase 1 trial shows Temferon — a gene-engineered stem cell therapy — safely delivers interferon-α into glioblastoma tumors with no dose-limiting toxicities.
Combining CD38 and PD-1 inhibitors produced durable remissions in relapsed NK/T-cell lymphoma, with median response duration exceeding 29 months.
